SCHEMBL222875

SCHEMBL222875

O=S(=O)(Cl)N1CCOCC1

nearest known ligand 0.65

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.65
CA7 P43166 1/20 0.65
CA14 Q9ULX7 1/20 0.65
SMN1; SMN2 Q16637 4/20 0.54
TSHR P16473 3/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
POLB P06746 4/20 0.45
LMNA P02545 1/20 0.41
MEN1 O00255 1/20 0.39
GAA P10253 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27781420 0.83
SCHEMBL4724826 0.79 CA12 (1.00) CA12CA7CA14SMN1; SMN2TSHR
SCHEMBL22003894 0.77
SCHEMBL2261416 0.77 POLB (0.42) CA12CA7CA14SMN1; SMN2TSHR
SCHEMBL898965 0.77 CA12 (0.65) CA12CA7CA14SMN1; SMN2TSHR
SCHEMBL490315 0.77 CA12 (0.65) CA12CA7CA14SMN1; SMN2TSHR
SCHEMBL995945 0.74 CA12 (0.62) CA12CA7CA14SMN1; SMN2TSHR
SCHEMBL12856096 0.74 CA12 (0.62) CA12CA7CA14SMN1; SMN2TSHR
SCHEMBL108245 0.74 CA12 (0.62) CA12CA7CA14SMN1; SMN2TSHR
SCHEMBL16692519 0.74 CA12 (0.62) CA12CA7CA14SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 736 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010115869-A1 PROPOFOL PHOSPHONYL DERIVATIVES, SYNTHESIS, AND USE IN LONG ACTING FORMULATIONS SEPS PHARMA N.V. (BE) 2010-10-14 WO claimed
EP-4746966-A1 4-AMINO-2,6-BIS(PHENYLMETHYLENE)CYCLOHEXANONES AND THEIR USE Ustav Organicke Chemie a Biochemie AV CR, v.v.i. (CZ) 2026-05-27 EP disclosed
EP-4727652-A1 (HETERO)ARYL-SULFONAMIDE COMPOUNDS AS MODULATORS OF GPR35 ThirtyFiveBio Limited (GB) 2026-04-22 EP disclosed
EP-4720046-A1 SULFONAMIDE COMPOUNDS AS CAV2.3 ANTAGONISTS Lario Therapeutics Limited (GB) 2026-04-08 EP disclosed
US-12570613-B2 Imidazoquinoline or benzoindazolone compound and intermediate for preparing same LMITO THERAPEUTICS INC. (KR) 2026-03-10 US disclosed
EP-4698520-A1 RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF Gandeeva Therapeutics, Inc. (US) 2026-02-25 EP disclosed
EP-4676926-A1 BICYCLIC HETEROARYL COMPOUNDS FOR USE AS GPR35 MODULATORS ThirtyFiveBio Limited (GB) 2026-01-14 EP disclosed
US-20250295683-A1 HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2025-09-25 US disclosed
US-20250236610-A1 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF BEIGENE, LTD. (KY) 2025-07-24 US disclosed
WO-2025133610-A1 INHIBITORY COMPOUNDS LOQUS23 THERAPEUTICS LIMITED (GB) 2025-06-26 WO disclosed
US-4935405-A Nor-statine and nor-cyclostatine polypeptides PFIZER INC. (US) 1990-06-19 US disclosed
US-4814342-A Nor-statine and nor-cyclostatine polypeptides PFIZER INC. (US) 1989-03-21 US disclosed
EP-0266950-A2 Nor-statine and nor-cyclostatine polypeptides PFIZER INC. (US) 1988-05-11 EP disclosed
CN-87101499-A Preparation method of n-statinib and n-cyclostatini polypeptide 1988-05-11 CN disclosed
US-4256831-A FOR COLOR DIFFUSION TRANSFER KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1981-03-17 US disclosed
US-4252804-A TRANQUILIZERS, ANTICONVULSANTS, MUSCLE RELAXANTS METABIO-JOULLIE (FR) 1981-02-24 US disclosed
US-4247629-A FOR DIFFUSION TRANSFER KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1981-01-27 US disclosed
EP-0010249-A2 Herbicidal agents, process for their preparation and their use in combating weeds BAYER AG (DE) 1980-04-30 EP disclosed
EP-0010250-A2 Use of Sulfonanilides in inhibition of plant growth BAYER AG (DE) 1980-04-30 EP disclosed
US-4067741-A Hardening photographic layers containing silver halide with a 1-sulphonyl-4-amino-pyridinium salt AGFA-GEVAERT, A.G. (DT) 1978-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250295683-A1 HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF CYP4F11, CYP51A1, CYP4A11 CA12 1835/4885CA7 1282/4885CA14 1735/4885
US-12570613-B2 Imidazoquinoline or benzoindazolone compound and intermediate for preparing same NQO1, CBR1, NFE2L2 CA12 4686/4885CA7 3055/4885CA14 4680/4885
US-20250236610-A1 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF HIPK1, HIPK3, HIPK2 CA12 4782/4885CA7 4484/4885CA14 4749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.